SCHEMBL29498754

SCHEMBL29498754

CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP3 Q9NY33 5/20 0.61
DPP4 P27487 2/20 0.61
NTSR2 O95665 1/20 0.51
NTSR1 P30989 1/20 0.51
SORT1 Q99523 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
MPO P05164 1/20 0.50
MAPT P10636 1/20 0.50
TSHR P16473 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
HIF1A Q16665 1/20 0.50
TACR1 P25103 2/20 0.49
CAPN1 P07384 2/20 0.48
CTSB P07858 2/20 0.48
BCHE P06276 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30051435 0.93 DPP4 (0.58) DPP3DPP4NTSR2NTSR1SORT1
SCHEMBL30051442 0.91 DPP4 (0.62) DPP3DPP4NTSR2NTSR1SORT1
SCHEMBL29842186 0.89 DPP3 (0.65) DPP3DPP4NTSR2NTSR1SORT1
SCHEMBL30051283 0.88 DPP3 (0.61) DPP3DPP4NTSR2NTSR1SORT1
SCHEMBL12340711 0.86 DPP4 (0.70) DPP3DPP4MEN1KMT2AKDM4E
SCHEMBL8236885 0.86 DPP4 (0.70) DPP3DPP4MEN1KMT2AKDM4E
SCHEMBL31474499 0.86 DPP4 (0.61) DPP3DPP4NTSR2NTSR1SORT1
SCHEMBL30052255 0.86 DPP3 (0.69) DPP3DPP4MEN1KMT2ATACR1
SCHEMBL29963309 0.85 DPP3 (0.64) DPP3DPP4NTSR2NTSR1SORT1
SCHEMBL30051252 0.85 DPP3 (0.65) DPP3DPP4NTSR2NTSR1SORT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 US disclosed
US-20240240246-A1 ENZYME-PORE CONSTRUCTS OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2024-07-18 US disclosed
US-11859247-B2 Enzyme-pore constructs OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2024-01-02 US disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 US disclosed
CN-113035291-B Method for designing DPP-IV inhibitory peptide by computer-assisted medicine, DPP-IV inhibitory peptide and application thereof 广东药科大学 2022-04-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP DPP3 25/4885DPP4 43/4885NTSR2 2464/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD DPP3 64/4885DPP4 73/4885NTSR2 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.